ATE126056T1 - Mittel zur behandlung von seniler demenz, gedächtnisstörungen und ähnlichen zuständen. - Google Patents

Mittel zur behandlung von seniler demenz, gedächtnisstörungen und ähnlichen zuständen.

Info

Publication number: ATE126056T1
Authority: AT; Austria
Prior art keywords: dementia; seniel; agents; treatment; afgf
Prior art date: 1989-03-16

Application number

AT90302851T

Other languages

English (en)

Inventor

Kunio C O Central Resear Torii

No - Suzuki-Cho Inc

Yutaka Oomura

Kazuo Sasaki

Hiroyuki C O Central Re Kojima

Co Inc No - Suzuki Ajinomoto

Original Assignee

Ajinomoto Kk

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-03-16

Filing date

1990-03-16

Publication date

1995-08-15

1990-03-16 Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk

1995-08-15 Application granted granted Critical

1995-08-15 Publication of ATE126056T1 publication Critical patent/ATE126056T1/de

Links

206010012289 Dementia Diseases 0.000 title 1
208000026139 Memory disease Diseases 0.000 title 1
102000003971 Fibroblast Growth Factor 1 Human genes 0.000 abstract 4
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 abstract 4
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
239000000126 substance Substances 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
150000008575 L-amino acids Chemical class 0.000 abstract 1
206010039966 Senile dementia Diseases 0.000 abstract 1
210000004556 brain Anatomy 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
239000008103 glucose Substances 0.000 abstract 1
230000002093 peripheral effect Effects 0.000 abstract 1
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 abstract 1
239000002644 phorbol ester Substances 0.000 abstract 1
230000028327 secretion Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)

AT90302851T 1989-03-16 1990-03-16 Mittel zur behandlung von seniler demenz, gedächtnisstörungen und ähnlichen zuständen. ATE126056T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP1064057A JP2814529B2 (ja)	1989-03-16	1989-03-16	虚血性脳障害治療薬

Publications (1)

Publication Number	Publication Date
ATE126056T1 true ATE126056T1 (de)	1995-08-15

Family

ID=13247084

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT90302851T ATE126056T1 (de)	1989-03-16	1990-03-16	Mittel zur behandlung von seniler demenz, gedächtnisstörungen und ähnlichen zuständen.

Country Status (7)

Country	Link
US (1)	US5693614A (de)
EP (1)	EP0388226B1 (de)
JP (1)	JP2814529B2 (de)
AT (1)	ATE126056T1 (de)
CA (1)	CA2012214A1 (de)
DE (1)	DE69021415T2 (de)
ES (1)	ES2077640T3 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2061380B1 (es) *	1992-11-23	1995-07-01	Boehringer Ingelheim Espana	Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.
FR2717495B1 (fr) *	1994-03-18	1996-04-12	Rhone Poulenc Rorer Sa	Virus recombinants, préparation et utilisation en thérapie génique.
FR2717823B1 (fr) *	1994-03-23	1996-04-26	Rhone Poulenc Rorer Sa	Virus recombinants, préparation et utilisation en thérapie génique.
FR2726575B1 (fr) *	1994-11-09	1996-12-20	Rhone Poulenc Rorer Sa	Virus recombinants, preparation et utilisation en therapie genique
IL113052A0 (en) *	1994-03-23	1995-06-29	Rhone Poulenc Rorer Sa	Recombinant viruses, their preparation and their use in gene therapy
EP0741143B1 (de) *	1995-04-25	2005-07-06	Ajinomoto Co., Inc.	Fibroblastenwachstumsfragmente
JPH1053521A (ja) *	1996-08-12	1998-02-24	Kagaku Gijutsu Shinko Jigyodan	脳内グルタミン酸の活性抑制剤および活性増強剤
WO2000056328A1 (en)	1999-03-19	2000-09-28	Enos Pharmaceuticals, Inc.	Increasing cerebral bioavailability of drugs
JP2003261456A (ja) *	2002-03-08	2003-09-16	Howaizu:Kk	脳の老化予防剤
US6951658B1 (en) *	2003-07-08	2005-10-04	Pearson Research & Development Limited	Emu-based compositions for mental well-being and method of use
JP2008056566A (ja) *	2004-12-28	2008-03-13	Toudai Tlo Ltd	低酸素応答促進剤
WO2006077954A1 (ja) *	2005-01-21	2006-07-27	Kyowa Hakko Kogyo Co., Ltd.	神経疾患治療剤
JP2013060406A (ja) *	2011-09-15	2013-04-04	Kyowa Hakko Bio Co Ltd	脳疲労改善用経口剤
JP2016121194A (ja) *	2016-04-05	2016-07-07	協和発酵バイオ株式会社	脳疲労改善用経口剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4378347A (en) *	1980-06-30	1983-03-29	Franco Wayne P	Composition for treating the heart for myocardial infarction
US4296100A (en) *	1980-06-30	1981-10-20	Franco Wayne P	Method of treating the heart for myocardial infarction
US4444760A (en) *	1983-06-17	1984-04-24	Merck & Co., Inc.	Purification and characterization of a protein fibroblast growth factor
JPS61501564A (ja) *	1984-03-01	1986-07-31	ア−ク，バ−ノン	老人の記憶疾患の治療方法
US4923696A (en) *	1987-05-04	1990-05-08	Baylor College Of Medicine	Method to prepare a neurotrophic composition
US5057494A (en) *	1988-08-03	1991-10-15	Ethicon, Inc.	Method for preventing tissue damage after an ischemic episode

1989
- 1989-03-16 JP JP1064057A patent/JP2814529B2/ja not_active Expired - Lifetime
1990
- 1990-03-15 CA CA002012214A patent/CA2012214A1/en not_active Abandoned
- 1990-03-16 ES ES90302851T patent/ES2077640T3/es not_active Expired - Lifetime
- 1990-03-16 AT AT90302851T patent/ATE126056T1/de not_active IP Right Cessation
- 1990-03-16 DE DE69021415T patent/DE69021415T2/de not_active Expired - Lifetime
- 1990-03-16 EP EP90302851A patent/EP0388226B1/de not_active Expired - Lifetime
1994
- 1994-06-14 US US08/261,050 patent/US5693614A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES2077640T3 (es)	1995-12-01
EP0388226A2 (de)	1990-09-19
US5693614A (en)	1997-12-02
EP0388226A3 (de)	1992-01-02
EP0388226B1 (de)	1995-08-09
JPH02243621A (ja)	1990-09-27
DE69021415D1 (de)	1995-09-14
DE69021415T2 (de)	1996-04-25
CA2012214A1 (en)	1990-09-16
JP2814529B2 (ja)	1998-10-22

Similar Documents

Publication	Publication Date	Title
DE69021415D1 (de)	1995-09-14	Mittel zur Behandlung von seniler Demenz, Gedächtnisstörungen und ähnlichen Zuständen.
ATE275383T1 (de)	2004-09-15	Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen
DE3779149D1 (de)	1992-06-25	Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
ATE91628T1 (de)	1993-08-15	Sauerwiderstehender fibroblast-wachstumsfaktor, zubereitung zur behandlung von magen-darmweggeschw¨rkrankheiten.
DE69028535D1 (de)	1996-10-17	Herstellung des vaskulären endothelialen zellwachstumsfaktors
DE68923819D1 (de)	1995-09-21	Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
ATE256475T1 (de)	2004-01-15	Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
EP0693928A4 (de)	1998-06-03	Aminozucker- und glykosaminoglykanzusammensetzung zur behandlung und reparatus von bindegewebe
ATE280577T1 (de)	2004-11-15	Oxa-säuren und verwandte verbindungen zur behandlung von störungen der haut
DE69634301D1 (de)	2005-03-10	Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf)
DE68908971D1 (de)	1993-10-14	Verwendung von physiologisch wirksamen Substanzen zur Herstellung von Medikamenten für Gehirn- und Nervenerkrankungen.
DE3856594D1 (de)	2008-11-27	Mittel zur behandlung der alzheimer-krankheit
ATE71629T1 (de)	1992-02-15	Methylenphosphonalkylphosphinate, pharmazeutische zubereitungen und verfahren zur behandlung abnormalen kalzium- und phosphat-stoffwechsels.
DE3878313D1 (de)	1993-03-25	Taurohyodeoxycholsaeure zur behandlung von gallenwegssteinen und gallenstoerungen.
ATE107515T1 (de)	1994-07-15	Zusammensetzung zur behandlung von entzündung.
DE69531004D1 (de)	2003-07-10	p277 PEPTIDANALOGE, PHARMAZEUTISCHE ZUSAMMENSTELLUNG DAVON ZUR BEHANDLUNG UND DIAGNOSE VON DIABETES
DE68921413D1 (de)	1995-04-06	Verbindungen und Zusammensetzungen zur Anwendung bei Methoden zur Behandlung und Prophylaxe von Pneumocystis Carinii Pneumonia und anderen Krankheiten.
ATE98121T1 (de)	1993-12-15	Fettsaeuren zur behandlung und praevention von hautschaeden durch radiotherapie.
DE3778852D1 (de)	1992-06-11	Arzneimittel enthaltend das gewebeprotein pp4, verfahren zur herstellung von pp4 und zu seiner pasteurisierung sowie die verwendung von pp4.
ATE290393T1 (de)	2005-03-15	Milchsäurebakterien zur behandlung und prophylaxe von giardiasis
ATE336992T1 (de)	2006-09-15	Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz- erkrankungen
ATE79265T1 (de)	1992-08-15	Mittel zur behandlung mykotischer, mikrobischer und anderer gewebsschaedigender und pathologischer manifestationen und gewebsdeformationen.
DE69408394D1 (de)	1998-03-12	4-Piperidino-piperidin zur Behandlung von Tumoren
DE3751510D1 (de)	1995-10-12	Düse zur Behandlung von Fäden.
FI944656A0 (fi)	1994-10-05	Uudet kardioprotektiivset aineet

Legal Events

Date	Code	Title	Description
1996-02-15	UEP	Publication of translation of european patent specification
2010-06-15	EELA	Cancelled due to lapse of time